StevenMFruchtmanMD

PubMed

• 16 citations
  Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study
  Shyamala C. Navada, Guillermo Garcia-Manero, Rosalie Odchimar-Reissig, Naveen Pemmaraju, Yesid Alvarado
  Leukemia Research. 2020-05-12
• 9 citations
  Proceedings of the fifth international RASopathies symposium: When development and cancer intersect
  Katherine A. Rauen, Lisa Schoyer, Lisa Schill, Beth Stronach, John G. Albeck
  American Journal of Medical Genetics. Part A. 2018-12-01
• 34 citations
  A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
  Shyamala C. Navada, Steven M. Fruchtman, Rosalie Odchimar-Reissig, Erin P. Demakos, Michael E. Petrone
  Leukemia Research. 2018-01-01

Abstracts/Posters

• Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)
  Steven M. Fruchtman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidin...
  Steven M. Fruchtman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018